Mood and emotional eating in adults starting GLP-1 weight-loss medicines
Follows adults with obesity starting GLP-1 medicines, looking at mood and emotional eating.
Key facts
- Who runs it
- TC Erciyes University
- Where
- Kayseri, TürkiyeSee the site
- Trial code
- Registry title
- Evaluation of Anhedonia and Emotional Eating in Individuals Using GLP-1 Receptor Agonists
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Record updated
- 3 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have just started a GLP-1 receptor agonist medicine to lose weight. Their mood and emotional eating are checked at the start and after 6 months.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- Must be newly started on GLP-1 receptor agonist treatment for weight reduction.
Main reasons for not taking part
- Using GLP-1 receptor agonists for a reason other than weight loss
- Cognitive, neurological or severe psychiatric conditions that prevent filling in the questionnaires
- Cannot read and understand Turkish
- Not taking part or dropping out at the 6-month follow-up
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age 18 years or older
- Newly initiated on GLP-1 receptor agonist treatment for weight reduction
- Willingness to participate in evaluations at baseline and at the 6-month follow-up
- Ability to read and understand Turkish and possess the cognitive capacity to answer questionnaire items
- Voluntary provision of written informed consent
Who cannot take part
- Cognitive, neurological, or severe psychiatric conditions preventing completion of self-report questionnaires
- Use of GLP-1 receptor agonists for indications other than weight loss
- Substantial missing, inconsistent, or unverifiable questionnaire data compromising analysis integrity
- Non-participation or dropout at the 6-month follow-up evaluation
Where in Türkiye
- Erciyes University Medical Faculty Hospitals, Department of Endocrinology and MetabolismKayseri, TürkiyeContact: Hasan Durmuş, MD, Assoc. Prof.Taking people
About the trial
What the trial wants to find out
This prospective observational study evaluates the longitudinal changes in anhedonia levels and emotional eating behaviors among adult individuals initiating glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss. Participants are assessed at baseline (treatment initiation) and after a 6-month follow-up period using standardized psychometric instruments.
The group in the trial
- GLP-1 Receptor Agonist Group
Adult participants who have newly initiated GLP-1 receptor agonist treatment for weight reduction and are evaluated at baseline and at 6 months.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Longitudinal Evaluation of Anhedonia and Emotional Eating Behavior in Individuals Using Glucagon-Like Peptide-1 Receptor Agonists
- Plain-language title
- Mood and emotional eating in adults starting GLP-1 weight-loss medicinesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 September 2026